Skip to main content

Advertisement

SpringerLink
Log in

Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Aim

This retrospective study was undertaken to clarify the characteristics of patients in whom vildagliptin exerts its HbA1c-lowering effect fully. The safety of vildagliptin was also examined.

Methods

Vildagliptin was administered as initial, additive, or exchange medication to 139 type 2 diabetic patients. Patients were excluded if they had a change in another oral hypoglycemic agent within 24 weeks after starting vildagliptin. The primary efficacy endpoint was the percentage of patients who attained HbA1c level <7 % at week 24.

Results

Vildagliptin significantly increased the percentage of patients who attained HbA1c level <7 %. It was significantly higher in patients with lower baseline HbA1c, higher C-peptide immunoreactivity (CPR) index [plasma CPR (ng/ml)/glucose (mg/dl) × 100], and in patients whose CPR index increased after the administration of vildagliptin. Categorical analyses by age, gender, and body mass index showed no significant differences among categories. There was no significant difference in HbA1c-lowering effect in the categories of oral hypoglycemic agents used concomitantly with vildagliptin, nor of hypoglycemic agents switched to vildagliptin. Logistic regression analyses indicated that the only factor contributing to the glucose-lowering effect of vildagliptin was baseline HbA1c. There were no changes in clinical parameters thought to be adverse events.

Conclusions

Administration of vildagliptin provided a significant and clinically relevant HbA1c-lowering effect irrespective of age, gender, BMI, and concomitantly or previously used hypoglycemic agents. Furthermore, not only high baseline CPR index, but also the increase in CPR index may be associated with the efficacy of this medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Richter B, Banderia-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4:753–68.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.

    Article  CAS  PubMed  Google Scholar 

  3. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl-peptidase IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–94.

    Article  CAS  PubMed  Google Scholar 

  4. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–55.

    Article  CAS  PubMed  Google Scholar 

  5. He YL, Yamaguchi M, Tarao S, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int J Clin Pharm Ther. 2010;48:582–95.

    Article  CAS  Google Scholar 

  6. Bergman AJ, Stevens C, Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.

    Article  CAS  PubMed  Google Scholar 

  7. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775–83.

    Article  CAS  PubMed  Google Scholar 

  8. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complicat. 2010;24:79–83.

    Article  PubMed  Google Scholar 

  9. Keating GM. Vildagliptin a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089–112.

    Article  CAS  PubMed  Google Scholar 

  10. Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus. A matching-adjusted indirect comparison of randomized trials. Clin Drug Invest. 2011;31:665–74.

    Article  CAS  Google Scholar 

  11. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34:1247–58.

    Article  CAS  PubMed  Google Scholar 

  12. Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–20.

    Article  CAS  PubMed  Google Scholar 

  13. Saisho Y, Miyakoshi K, Tanaka M, et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J. 2010;57:973–80.

    Article  PubMed  Google Scholar 

  14. The Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan. Tokyo: Nankodo; 2004 (in Japanese).

    Google Scholar 

  15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  CAS  PubMed  Google Scholar 

  16. Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.

    Article  PubMed  Google Scholar 

  17. Eposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13:594–603.

    Article  Google Scholar 

  18. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;89:216–23.

    Article  CAS  PubMed  Google Scholar 

  19. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with sulfonylurea. Diabetes Obes Metab. 2008;11:1047–56.

    Article  Google Scholar 

  20. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:20–2.

    Article  Google Scholar 

  21. Bando Y, Kanehara H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Invest. 2012;3:170–4.

    Article  CAS  Google Scholar 

  22. Prato SD, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of & #x03B2;-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–67.

    Article  PubMed  Google Scholar 

  23. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–5.

    Article  PubMed  Google Scholar 

  24. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed & #x03B2;-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103–9.

    Article  CAS  PubMed  Google Scholar 

  25. Goto A, Takaichi M, Kishimoto M, et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J. 2010;57:237–44.

    Article  CAS  PubMed  Google Scholar 

  26. Asano T, Kawamura M, Watanabe T, et al. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Jpn Diabetes Soc. 2008;51:759–63 (in Japanese).

    CAS  Google Scholar 

  27. Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J. 2011;58:315–22.

    Article  CAS  PubMed  Google Scholar 

  28. Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1 and cardiovascular risk. Nutr Metab Cardiovasc Dis. 2008;18:639–45.

    Article  CAS  PubMed  Google Scholar 

  29. Giorgino F, Leonardini A, Natalicchio A, et al. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest. 2011;34:69–77.

    Article  CAS  PubMed  Google Scholar 

  30. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

H.I. has received lecture fees from MSD and Novartis, and research grants from Sanofi-Aventis, Pfizer, Dainippon Sumitomo, Teijin, Takeda, Tanabe Mitsubishi, MSD, Daiichi Sankyo, Roche, and Eli Lilly. The other authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Masami Tanaka, Risa Sekioka, Takeshi Nishimura, Toshihide Kawai, Shu Meguro, Junichiro Irie, Yoshifumi Saisho & Hiroshi Itoh

Authors
  1. Masami Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Risa Sekioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihide Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shu Meguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junichiro Irie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshifumi Saisho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masami Tanaka.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanaka, M., Sekioka, R., Nishimura, T. et al. Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus. Diabetol Int 6, 197–205 (2015). https://doi.org/10.1007/s13340-014-0186-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-014-0186-7

Keywords

Search

Navigation